RxDoctor Payments Data

Louise Cheung

Family · Duarte, CANPI 1578818365

Payments from drug & device makers

$4,467in general payments, 2019–2025

Across 63 payments — averaging $70.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AstraZeneca$1K
  • Gilead$529
  • Merck$417
  • GE HealthCare$188
  • Tactile Systems Technology Inc$136
  • plus $375 from 7 others

What the payments were for

  • Food & beverage$2,90865%
  • Education$271%
  • Other$1,53134%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,467 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$31,351
Medicare patients
176
Services billed
365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate39$628,788
IbrancePalbociclib40$609,046
OrserduElacestrant Hcl13$283,485
TruqapCapivasertib13$276,442
VerzenioAbemaciclib25$273,325
LynparzaOlaparib13$173,207
Everolimus25$47,694
Exemestane22$5,716
Anastrozole156$3,016
Letrozole107$2,787
Gabapentin64$1,654
Tamoxifen Citrate36$1,207
Prochlorperazine Maleate40$804
Venlafaxine Hcl ErVenlafaxine Hcl14$508
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen18$303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$1,708$628,78839 claims
AstraZenecaTruqap, Lynparza$1,113$449,64926 claims
Stemline Therapeutics Inc.Orserdu$125$283,48513 claims
Lilly USA, LLCVerzenio$124$273,32525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Duarte

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →